Publication Library
Espansione's claims rest on a growing peer-reviewed footprint spanning dry eye disease, meibomian gland dysfunction and, increasingly, the retina. This page indexes the cornerstone references by indication. Comparative statements are made only where head-to-head data exists, in keeping with sound evidence practice.
Dry eye and meibomian gland dysfunction
The strongest evidence concerns meibomian gland dysfunction and is based on randomised controlled trials:
- Giannaccare et al., 2022, Cornea. A randomised controlled trial showing LM™ LLLT superior to OPE™ IPL on SPEED symptom scores and tear meniscus height at two-week follow-up in MGD.
- Leite et al., 2025, Revista da Sociedade Portuguesa de Oftalmologia. Combined OPE™ IPL plus LM™ LLLT on eye-light® plus my-mask® superior to an IPL-only comparator at eighteen-month follow-up in MGD.
- Castro et al., 2023. Combined therapy superior to IPL-only competitor devices on lipid layer thickness and OSDI.
- Meduri et al., 2022. Combined therapy superior to sodium hyaluronate 2 mg/ml eye drops on non-invasive breakup time and OSDI.
Dry age-related macular degeneration
The evidence in the posterior segment now includes a randomised controlled trial:
- Iovino et al., 2026, British Journal of Ophthalmology. The DRUSEN trial: a 12-month, multicentre, randomised, double-masked, sham-controlled trial in 138 eyes with early and intermediate dAMD. PBM on eye-light® significantly reduced mean drusen volume and improved best-corrected visual acuity versus sham (between-group difference 3.75 ETDRS letters, 95% CI 1.16 to 6.34), with no treated eye progressing to neovascular AMD (four such conversions occurred in the sham group) and no retinal phototoxicity.
- Borrelli et al., 2024, Ophthalmology and Therapy. Safety, tolerability and short-term efficacy of eye-light® photobiomodulation for dry AMD.
- Viggiano et al., 2025, Eye (Nature). PBM-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate AMD, with significant visual acuity improvement and drusen volume reduction at follow-up.
Surgical and perioperative care
- Solarino et al., 2026, Therapeutic Advances in Ophthalmology. A prospective, double-masked, randomised, sham-controlled trial of perioperative LM™ LLLT on eye-light® in Femto-LASIK patients. LLLT preserved tear meniscus height, Schirmer values and patient comfort (DEQ-5) at one and three months, where the sham group declined significantly. Tear-film stability measures (NIBUT, interferometry) did not differ significantly between groups.
- Giannaccare et al., 2024, British Journal of Ophthalmology. A randomised, double-masked, controlled trial of LM™ LLLT before and after cataract surgery for the prophylaxis of postoperative dry eye.
Guideline recognition
- TFOS DEWS III Management and Therapy Report, 2025, American Journal of Ophthalmology. Recognises LM™ LLLT (PBM) on eye-light® as beneficial across the tear film, the eyelids and the ocular surface. See TFOS DEWS III.
Breadth of the literature
Beyond these cornerstones, the wider literature includes work on chalazion, Sjögren's, Demodex, surgical applications and review articles. For the underlying biology, see the mechanism-of-action literature in basic science and in ophthalmology.
Full bibliography is available on our website at https://espansionegroup.it/bibliography
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.